Frontiers in Pharmacology,
Journal Year:
2024,
Volume and Issue:
15
Published: June 24, 2024
The
global
prevalence
of
Metabolic
Dysfunction-Associated
Steatotic
Liver
Disease
(MASLD)
is
increasing,
now
affecting
25%–30%
the
population
worldwide.
MASLD,
characterized
by
hepatic
steatosis,
results
from
an
imbalance
in
lipid
metabolism,
leading
to
oxidative
stress,
lipoperoxidation,
and
inflammation.
activation
autophagy,
particularly
lipophagy,
alleviates
steatosis
regulating
intracellular
levels.
Lutein,
a
carotenoid
with
antioxidant
anti-inflammatory
properties,
protects
against
liver
damage,
individuals
who
consume
high
amounts
lutein
have
lower
risk
developing
MASLD.
Evidence
suggests
that
could
modulate
autophagy-related
signaling
pathways,
such
as
transcription
factor
EB
(TFEB).
TFEB
plays
crucial
role
homeostasis
linking
autophagy
energy
metabolism
at
transcriptional
level,
making
potential
target
STARD3,
transmembrane
protein
binds
transports
cholesterol
sphingosine
lysosomes
endoplasmic
reticulum
mitochondria,
has
been
shown
transport
bind
affinity.
This
may
play
uptake
liver,
contributing
decrease
regulation
stress
review
summarizes
current
knowledge
on
pathways
it
involved
in,
its
relationship
pharmacological
strategy
treat
steatosis.
Frontiers in Nutrition,
Journal Year:
2025,
Volume and Issue:
12
Published: Jan. 27, 2025
Background
The
global
burden
of
non-alcoholic
steatohepatitis
(NASH)-related
liver
cancer
(NRLC)
is
increasing,
making
NASH
the
fastest-growing
cause
worldwide.
This
study
presents
a
comprehensive
analysis
NRLC
at
global,
regional,
and
national
levels,
further
categorized
by
age,
sex,
sociodemographic
index
(SDI).
Method
Data
on
from
Global
Burden
Disease,
Injuries,
Risk
Factors
(GBD)
2021
were
downloaded
levels.
numbers
age-standardized
rates
(ASRs)
incidence,
mortality,
disability-adjusted
life
years
(DALYs)
analyzed
to
quantify
NRLC.
Additionally,
percentage
changes
in
ASRs
used
identify
trends
1990
2021.
Results
Globally,
both
number
cases
for
increased
between
In
2021,
there
42,291
new
cases,
40,925
deaths,
995,475
DALYs
attributed
East
Asia,
South
Southeast
Asia
reported
highest
absolute
case
numbers,
while
Western,
Southern,
Eastern
Sub-Saharan
Africa
exhibited
ASRs.
From
Australasia,
Southern
Latin
America,
High-income
North
America
showed
most
significant
increases
incidence.
Nationally,
Mongolia,
Gambia,
Mozambique
ASR
2021.The
greatest
ASIR
occurred
Australia,
United
Kingdom,
New
Zealand
incidence
higher
men
with
peaking
80–89
years.
Similar
patterns
observed
NRLC-related
deaths
DALYs.
Regionally,
initially
declined
but
then
as
SDI
rose.
At
level,
consistently
decreased
SDI.
Conclusion
highlights
substantial
Males
older
individuals
bear
disease
burden,
considerable
variation
exists
across
different
regions
countries.
These
findings
provide
critical
insights
formulating
effective
strategies
prevent
manage
Annals of Hepatology,
Journal Year:
2022,
Volume and Issue:
27(6), P. 100706 - 100706
Published: April 13, 2022
Non-alcoholic
fatty
liver
disease
(NAFLD)
produces
high
morbidity
and
mortality
rates.
Its
worldwide
prevalence
is
25%,
but
evidence
from
Latin
America
(LA)
lacking.
We
aimed
to
estimate
the
of
NAFLD
in
adult
population
LA.
conducted
a
systematic
review
meta-analysis.
Data
were
collected
OVID,
Cochrane
Library
LILACS
search
engines.
used
terms
related
LA
countries.
Observational
studies
adults
who
born
live
included.
Two
reviewers
evaluated
articles,
extracted
data
assessed
risk
bias.
Discrepancies
resolved
by
consensus
or
third
reviewer.
A
validated
tool
was
assess
found
analyzed
19
articles
(n=5625).
The
general
captive
24%.
Populations
with
type
2
diabetes
mellitus
obesity
had
higher
mean
that
reached
68%.
concluded
average
around
Among
high-risk
groups,
this
value
increases
Further
using
appropriate
designs
are
required
for
an
accurate
Journal of Clinical Medicine,
Journal Year:
2024,
Volume and Issue:
13(16), P. 4857 - 4857
Published: Aug. 17, 2024
The
prevalence
of
nonalcoholic
fatty
liver
disease
(NAFLD)
is
likely
to
be
approaching
38%
the
world's
population.
It
predicted
become
worse
and
main
cause
morbidity
mortality
due
hepatic
pathologies.
particularly
worrying
that
NAFLD
increasingly
diagnosed
in
children
closely
related,
among
other
conditions,
insulin
resistance
metabolic
syndrome.
Against
this
background
concern
awareness
patients
with
low;
one
study,
almost
96%
adult
USA
were
not
aware
their
disease.
Thus,
studies
on
therapeutic
tools
used
treat
are
extremely
important.
One
promising
treatment
a
well-formulated
ketogenic
diet
(KD).
aim
paper
present
review
available
publications
current
state
knowledge
effect
KD
NAFLD.
This
includes
characteristics
key
factors
(from
point
view
regression),
which
exerts
its
effects,
i.e.,
reduction
body
weight,
elimination
fructose
monosaccharides,
limitation
total
carbohydrate
intake,
anti-inflammatory
ketosis
state,
or
modulation
gut
microbiome
metabolome.
In
context
evidence
for
effectiveness
regression
NAFLD,
also
suggests
important
role
taking
responsibility
one's
own
health
through
increasing
self-monitoring
self-education.
Frontiers in Cardiovascular Medicine,
Journal Year:
2022,
Volume and Issue:
9
Published: Sept. 12, 2022
Non-alcoholic
fatty
liver
disease
(NAFLD)
was
previously
a
neglected
that
is
now
becoming
worldwide
pandemic.
A
better
understanding
of
its
incidence
and
long-term
trends
will
help
to
increase
public
awareness
the
development
future
prevention
strategies.The
rates
NAFLD
during
1990-2019
were
collected
from
Global
Burden
Disease
Study
2019
database
according
following
parameters:
sex,
age,
socio-demographic
index,
geographical
region.
Estimated
annual
percentage
changes
joinpoint
models
used
assess
trend
NAFLD,
an
age-period-cohort
model
extents
period,
cohort
effects.Adult
males,
postmenopausal
females,
Latin
American
populations,
people
in
developing
countries
had
high
risk
NAFLD.
The
indicated
new
increasing
2005.
Age
factor
affecting
incidence,
with
this
effect
more-recent
periods.
Younger
birth
cohorts
lower
risks
NAFLD.Recent
measures
for
have
achieved
good
initial
results.
However,
it
remains
priority
condition,
develop
diagnostic
criteria,
identify
cost-effective
screening
methods,
seek
policy
support
act
against
which
be
major
health
problem
future.
Liver International,
Journal Year:
2025,
Volume and Issue:
45(5)
Published: April 3, 2025
ABSTRACT
Metabolic
dysfunction‐associated
steatotic
liver
disease
(MASLD)
and
alcohol‐associated
(ALD)
are
the
major
contributors
to
burden
globally.
The
rise
in
these
conditions
is
linked
obesity,
type
2
diabetes,
metabolic
syndrome
increased
alcohol
consumption.
MASLD
ALD
share
risk
factors,
pathophysiology
histological
features
but
differ
their
thresholds
for
use,
definition
does
not
require
presence
of
dysfunction.
A
recent
multi‐society
consensus
overhauled
nomenclature
steatosis
introduced
term
MetALD
describe
patients
with
dysfunction
who
drink
more
than
those
less
ALD.
This
new
terminology
aims
enhance
understanding
management
poses
challenges,
such
as
need
accurately
measure
consumption
research
clinical
practice
settings.
Recent
studies
show
that
has
significant
implications
patient
management,
it
associated
mortality
risks
severe
outcomes
compared
alone.
face
progression,
cancer
cardiovascular
disease.
diagnosis
involves
adequate
quantification
use
through
standardised
questionnaires
and/or
biomarkers
well
proper
assessment
stage
progression
using
non‐invasive
tools
including
serologic
markers,
imaging,
elastography
techniques
genetic
testing.
Effective
requires
addressing
both
alcohol‐related
factors
improve
outcomes.
review
intends
provide
a
comprehensive
overview
MetALD,
covering
pathogenesis,
potential
diagnostic
approaches,
strategies
emerging
therapies.
